IRLAB Therapeutics AB Class A Statistics
IRLAB Therapeutics AB Class A (6IRA) Stock Statistics & Valuation Metrics
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of EUR 28.64M. The enterprise value is EUR 95.31M.
- Market Cap
- EUR 28.64M
- Enterprise Value
- EUR 95.31M
Share Statistics
IRLAB Therapeutics AB Class A has 148,632,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 148,632,140
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is -3.58 and return on invested capital (ROIC) is -152.21%.
- Return on Equity (ROE)
- -3.58
- Return on Assets (ROA)
- -0.80
- Return on Invested Capital (ROIC)
- -152.21%
- Return on Capital Employed (ROCE)
- -3.01
- Revenue Per Employee
- 1.85M
- Profits Per Employee
- -3.55M
- Employee Count
- 31
- Asset Turnover
- 0.42
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is -0.95. IRLAB Therapeutics AB Class A’s PEG ratio is -0.01.
- PE Ratio
- -0.95
- PS Ratio
- 1.16
- PB Ratio
- 0.54
- Price to FCF
- -1.51
- Price to Operating Cash Flow
- -0.86
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 57.46M and earned -110.01M in profits. Earnings per share was -1.64.
- Revenue
- 57.46M
- Gross Profit
- -92.35M
- Operating Income
- -92.35M
- Pretax Income
- -110.01M
- Net Income
- -110.01M
- EBITDA
- -88.03M
- Earnings Per Share (EPS)
- -1.64
Cash Flow
In the last 12 months, operating cash flow was -61.05M and capital expenditures 0, giving a free cash flow of -61.05M billion.
- Operating Cash Flow
- -61.05M
- Free Cash Flow
- -61.05M
- Free Cash Flow per Share
- -0.72
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -66.25%
- Earnings Yield
- -102.24%
Stock Price Statistics
- Beta
- 0.17
- 52-Week Price Change
- -3.88%
- 50-Day Moving Average
- 0.16
- 200-Day Moving Average
- 0.14
- Relative Strength Index (RSI)
- 66.62
- Average Volume (3m)
- ―
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is Nov 13, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 26, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 97.51%
- Current Ratio
- 0.80
- Quick Ratio
- 0.80
- Debt to Market Cap
- 0.20
- Net Debt to EBITDA
- 0.59
- Interest Coverage Ratio
- -5.13
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is -2.03, with an EV/FCF ratio of -1.35.
- EV to Sales
- 1.04
- EV to EBITDA
- -2.03
- EV to Free Cash Flow
- -1.35
- EV to Operating Cash Flow
- -1.35
Balance Sheet
IRLAB Therapeutics AB Class A has EUR 34.22M in cash and marketable securities with EUR 24.20M in debt, giving a net cash position of EUR 10.02M billion.
- Cash & Marketable Securities
- EUR 34.22M
- Total Debt
- EUR 24.20M
- Net Cash
- EUR 10.02M
- Net Cash Per Share
- EUR 0.07
- Tangible Book Value Per Share
- EUR 0.59
Margins
Gross margin is -58.37%, with operating margin of -58.37%, and net profit margin of -67.87%.
- Gross Margin
- -58.37%
- Operating Margin
- -58.37%
- Pretax Margin
- -67.87%
- Net Profit Margin
- -67.87%
- EBITDA Margin
- -51.11%
- EBIT Margin
- -56.35%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 9.35%
- EPS Growth Forecast
- 65.77%
